TY - BOOK AU - Peters, Lisa TI - Report from the 2018 consensus conference on immunomodulating agents in thoracic transplantation: Access, formulations, generics, therapeutic drug monitoring, and special populations SN - 1053-2498 PY - 2020/// KW - *Consensus KW - *Drugs, Generic/pd [Pharmacology] KW - *Graft Rejection/pc [Prevention & Control] KW - *Immunosuppression/mt [Methods] KW - *Immunosuppressive Agents/pd [Pharmacology] KW - *Lung Transplantation KW - Drug Substitution KW - Humans KW - MedStar Washington Hospital Center KW - Pharmacy KW - Editorial N1 - Available online from MWHC library: 1999 - present, Available in print through MWHC library:1999-2007 N2 - In 2009, the International Society for Heart and Lung Transplantation recognized the importance and challenges surrounding generic drug immunosuppression. As experience with generics has expanded and comfort has increased, substantial issues have arisen since that time with other aspects of immunomodulation that have not been addressed, such as access to medicines, alternative immunosuppression formulations, additional generics, implications on therapeutic drug monitoring, and implications for special populations such as pediatrics and older adults. The aim of this consensus document is to address critically each of these concerns, expand on the challenges and barriers, and provide therapeutic considerations for practitioners who manage patients who need to undergo or have undergone cardiothoracic transplantation. Copyright (c) 2020 International Society for Heart and Lung Transplantation. Published by Elsevier Inc. All rights reserved UR - https://dx.doi.org/10.1016/j.healun.2020.06.024 ER -